Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Foreign Drug Inspection Program Before House Subcommittee on Oversight & Investigations
The hearing will focus on the FDA's ongoing struggle to inspect foreign drug manufacturing establishments, which export prescription and over-the-counter finished drugs and active pharmaceutical ingredients to the U.S. In his testimony, Mr. England will discuss reasons for the FDA's continuing difficulties to identify the scope of the market the agency regulates and to assess and mitigate safety risks associated with millions of annual imported drug shipments.
Mr. England spent 17 years with the FDA; his last three years as Regulatory Counsel to the Associate Commissioner for Regulatory Affairs. He is the co-author of the FDA Import Strategic Plan, the foundational document for the FDA's current Strategic Framework and Action Plan.
Mr. England is available to the news media to discuss his testimony, and the areas of:
-- Current issues related to the import of toys, food, and pharmaceuticals from China and other countries
-- Measurable solutions to the current FDA import crisis
-- Risk management applied by industry to the benefit of consumers
-- FDA regulatory compliance and enforcement and inspections issues
-- The intersection of Customs, FDA and other border agency jurisdictions, programs, and policies
Mr. England can be reached by contacting Debra Colbert, 301-565-5329, email@example.com; cell: 301-332-0813
Jones Walker, with more than 200 attorneys, provides the full range of legal services to a national and international corporate client base through offices in Florida, Louisiana, Texas, and Washington, D.C. For more information, visit www.joneswalker.com.
SOURCE Jones Walker
You May Also Like